A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
| Autor: | Gordon, Kenneth B., Leonardi, Craig L., Lebwohl, Mark, Blauvelt, Andrew, Cameron, Gregory S., Braun, Daniel, Erickson, Janelle, Heffernan, Michael |
|---|---|
| Zdroj: | In Journal of the American Academy of Dermatology December 2014 71(6):1176-1182 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect